Using small scaled high-throughput drug screening with 306 clinical and emerging cancer drugs on CR cells, Saeed et al. (2017) have identified Bcl-2 family inhibitor navitoclax as a potential treatment for castration-resistant prostate cancer (currently is being tested in a clinical trial) [24]. This evidence concerns the gene BCL2 and prostate cancer.